

Bertin Pharma also markets preanalytical products, EIA kits, antibodies & biochemicals for:

- Cardiology / Hypertension
- Diabetes / Obesity
- Endocrinology / Metabolism
- **▶** Inflammation
- Pharmacology
- Psychopharmacology
- **▶** Nitric Oxide
- Oncology / Apoptosis
- Oxidative injury
- Cell signaling
- Drug metabolism





European patent # 89 139 552 U.S. patent # 50 47 330

# Angiotensin II Enzyme Immunoassay kit #A05880.96 wells

For research laboratory use only Not for human diagnostic use

This assay has been developed & validated by Bertin Pharma



#A11880 Version: 0117

# Table of contents

| <b></b>     | Precaution for use                   | 6  |
|-------------|--------------------------------------|----|
| <b>•</b>    | Background                           | 8  |
|             | Principle of the assay               | 10 |
| <b>•</b>    | Materials and equipment required     | 12 |
| <b>\</b>    | Sample collection and preparation    | 13 |
| <b>\</b>    | Reagent preparation                  | 18 |
| <b>&gt;</b> | Assay procedure                      | 21 |
|             | Data analysis                        | 27 |
|             | Acceptable range                     | 28 |
|             | Typical results                      | 29 |
|             | Assay validation and characteristics | 30 |
|             | Troubleshooting                      | 33 |
|             | Bibliography                         | 35 |

# 96 wells Storage: -20°C Expiry date: stated on the package

#### This kit contains:

| Designation                                     | Colour of cap           | Item #                 | Quantity<br>per kit | Form        |
|---|-------------------------|------------------------|---------------------|-------------|
| Angiotensin II precoated<br>96-well Strip Plate | Blister with zip        | A08880.1 ea            | 1                   |             |
| Angiotensin II Tracer                           | Green                   | A04880.100 dtn         | 1                   | Lyophilised |
| Angiotensin II Standard                         | Blue with red<br>septum | A06880.1 ea            | 2                   | Lyophilised |
| Angiotensin II Quality<br>Control               | Green with red septum   | A10880.1 ea            | 2                   | Lyophilised |
| Glutaraldehyde                                  | White with red septum   | A13880.1 ea            | 1                   | Liquid      |
| Borane Trimethylamine                           | Silver                  | A14880.1 ea            | 2                   | Powder      |
| EIA Buffer                                      | Blue                    | A07000.1 ea            | 1                   | Lyophilised |
| Wash Buffer                                     | Silver                  | A17000.1 ea            | 1                   | Liquid      |
| Tween 20  | Transparent             | A12000.1 ea            | 1                   | Liquid      |
| Ellman's Reagent 49+1                           | Black with red septum   | A09000_49+1.100<br>dtn | 2                   | Lyophilised |
| Technical Booklet                               | -                       | A11880                 | 1                   |             |
| Well cover Sheet                                | -                       | -                      | 1                   | -           |

Each kit contains sufficient reagents for 96 wells. This allows for the construction of one standard curve in duplicate and the assay of 36 samples in duplicate.

If you want to use the kit in two times, we provide one additional vial of Standard, one of Quality Control and one of Ellman's Reagent.

#### Precaution for use

# Users are recommended to carefully read all instructions for use before starting work.

Each time a new pipette tip is used, aspirate a sample or reagent and expel it back into the same vessel. Repeat this operation two or three times before distribution in order to equilibrate the pipette tip.

- > For research laboratory use only
- > Not for human diagnostic use
- Do not pipet liquids by mouth
- Do not use kit components beyond the expiration date
- Do not eat, drink or smoke in area in which kit reagents are handled
- Avoid splashing

The total amount of reagents contains less than 100 µg of sodium azide. Flush the drains thoroughly to prevent the production of explosive metal azides.



Borane Trimethylamine is highly toxic. Handle this reagent with care.

Wearing gloves, laboratory coat and glasses is recommended when assaying kit materials and samples.

### **Temperature**

Unless otherwise specified, all the experiments are done at room temperature (RT), that is around +20°C. Working at +25°C or more affects the assay and decreases its efficiency.

### Background

#### Acetylcholinesterase AChE® Technology

Acetylcholinesterase (AChE®), the enzymatic label for EIA, has the fastest turnover rate of any enzymatic label. This specific AChE is extracted from the electric organ of the electric eel, *Electrophorus electricus*, and is capable of massive catalytic turnover during the generation of the electrochemical discharges. The use of AChE as enzymatic label for EIA has been patented by the French academic research Institute CEA [1, 2, 3], and Bertin Pharma, formerly known as SPI-Bio, has expertise to develop and produce EIA kits using this technology.

AChE® assays are revealed with Ellman's Reagent, which contains acetylthiocholine as a substrate. The final product of the enzymatic reaction (5-thio-2-nitrobenzoic acid), is bright yellow and can be read at 405-414 nm. AChE® offers several advantages compared to enzymes conventionally used in EIAs:

- Kinetic superiority and high sensitivity: AChE® shows true first-order kinetics with a turnover of 64,000 sec-¹. That is nearly 3 times faster than Horseradish Peroxidase (HRP) or alkaline phosphatase. AChE® allows a greater sensitivity than other labeling enzymes.
- Low background: non-enzymatic hydrolysis of acetylthiocholine in buffer is essentially absent. So, AChE® allows a very low background and an increased signal/noise ratio compared to other substrate of enzymes which is inherently unstable.

- Wide dynamic range: AChE® is a stable enzyme and its activity remains constant for many hours as, unlike other enzymes, its substrate is not suicidal. This permits simultaneous assays of high diluted and very concentrated samples.
- > Versatility: AChE® is a completely stable enzyme, unlike peroxidase which is suicidal. Thus, if a plate is accidentally dropped after dispatch of the AChE® substrate (Ellman's Reagent) or if it needs to be revealed again, one only needs to wash the plate, add fresh Ellman's Reagent and proceed with a new development. Otherwise, the plate can be stored at +4°C with wash buffer in wells while waiting for technical advice from the Bioreagent Department.

### Angiotensin

The Renin-Angiotensin system is essential for the control of blood pressure.

Among the different peptides resulting from the proteolytic processing of angiotensinogen, the octapeptide Angiotensin II (AII) is the major hormone involved in the pathophysiology of hypertensive diseases as it mediates vasoconstrictor action.

It is the target of choice allowing proper estimation of the Renin-Angiotensin system *[4]*.

The peptidic sequence for Angiotensin II is highly conserved across mammalian species, this is why our kit cross-reacts with all mammalian samples.

#### Principle of the assay

The principle of this Enzyme ImmunoAssay (EIA) is summarised on the following page.

A specific monoclonal anti-Angiotensin II antibody is immobilised on a 96-well plate.


After immunological reaction with Angiotensin II and washing, the trapped molecule is covalently linked to the plate by the glutaraldehyde via amino groups [5, 6, 8].

After washing and denaturing treatment, Angiotensin II can react again with the acetylcholinesterase-labelled monoclonal antibody used as a tracer.

The plate is then washed and Ellman's Reagent (enzymatic substrate for AChE and chromogen) is added to the wells.

The AChE tracer acts on the Ellman's Reagent to form a yellow compound.

The intensity of the colour, which is determined by spectrophotometry, is proportional to the amount of tracer bound to the well and is proportional to the amount of Angiotensin II.



# Materials and equipment required

In addition to standard laboratory equipment, the following material is required:

#### For sample preparation:

- Phenyl-cartridges 3 mL with 500 mg resin #D30004
- > Methanol
- > HCI
- > UltraPure water
- Inhibitor cocktail #D05006

#### For the assay:

- > Precision micropipettes (20 to 1000 µL)
- Spectrophotometer plate reader (405 or 414 nm filter)
- Microplate washer (or washbottles)
- > Orbital microplate shaker
- > Multichannel pipette and disposable tips 30-300µL
- UltraPure water #A07001.1L
- > Polypropylene tubes



Water used to prepare all EIA reagents and buffers must be UltraPure (deionized & free from organic contaminant traces).

Otherwise, organic contamination can significantly affect the enzymatic activity of the tracer Acetylcholinesterase (AChE).

Do not use distilled water, HPLC-grade water or sterile water.

UltraPure Water #A07001.1L may be purchased from Bertin Pharma.

# Sample collection and preparation

#### General precautions

- All samples must be free from organic solvents prior to assay.
- Samples should be assayed immediately after collection or should be stored at -20°C.

#### Culture media samples

Tissue culture supernatants may be assayed directly. If the Angiotensin II concentration in the medium is high enough, the samples can be diluted with EIA Buffer. The assay can be performed without any modifications.

When assaying less concentrated samples (when samples cannot be diluted with EIA Buffer), dilute the Standard curve in the same culture medium as the one used in the experiment. This will ensure that the matrix for the standards is comparable to the samples.

We recommend that a standard curve be run first to ensure that the assay will perform in this particular medium.

#### Blood collection

Blood samples are collected in tubes kept on ice at +4°C and usually containing EDTA.

Since Angiotensin II is very unstable in biologic sample, we highly recommend using an inhibitor cocktail to prevent generation and/or degradation of Angiotensin II ex vivo [7].

Bertin Pharma offers the inhibitor cocktail ready to use #D05006, quantity sufficient for 10 mL, 50 mL or 200 mL of blood.

The samples are centrifuged at 3,000 g for 20 minutes at +4°C.

Samples should be immediately extracted or stored at -20°C until extraction.

Avoid thawing samples more than once.

### Extraction protocol

- Pre-wash phenyl cartridges with 1 mL of methanol, followed by 1 mL of water.
- Pass 2 ml of plasma through the cartridge and then wash it with 1 mL of water.
- Elute absorbed Angiotensin peptides with 0.5 mL of methanol.
- Evaporate the methanol to dryness either by vacuum centrifugation or by evaporation under a stream of dry nitrogen.
- Add 0.5 mL of EIA buffer, vortex and centrifuge at 3,000 g for 10 minutes at 4°C.

### Recovery and calculation

To determine the recovery, the sample may be split into two equal aliquots and one spiked with a known amount of Angiotensin II (approximately equal to the expected amount in the sample).

The recovery will be determined after purification by comparing the concentration of the spiked and unspiked samples.

Either the original concentration of the sample or the recovery factor can be determined by solving the following equations simultaneously:

z = recovery factor

X/a = original concentration of the unspiked sample in a known volume (a)

(X+Y)/b = concentration of the spiked sample (pg/mL) after adding a known amount (Y) in a final volume (b)

The concentration of the unspiked and spiked samples determined by the EIA are respectively equal to (X/a)z and [(X+Y)/b]z.

#### > Example

- Volume of the unspiked sample: a = 1mL
- Final volume of the spiked sample: b = 2 mL
- Concentration determined by EIA for the unspiked sample: (X/a)z = 8 pg/mL
- Concentration determined by EIA for the spiked sample: [(X+Y)/b]z = 16 pg/mL
- Quantity of spike: Y = 30 pg in 1mL

$$Xz = 8 \Leftrightarrow z = 8/X$$
 $[(X+30)/2]z = 16 \Leftrightarrow [(X+30)]z = 32$ 
thus,
 $[(X+30)]8/X = 32 \Leftrightarrow X+30 = 4X \Leftrightarrow 3X = 30 \Leftrightarrow X = 10$ 
and
 $Xz = 8 \Leftrightarrow z = 0.8$ 

#### > Note

To minimise the calculations, the standard should be concentrated enough so that the addition of the standard does not alter the volume of the sample (a = b) to any great degree (i.e., the assumption is made that the volume is not changed by the addition of the standard).

### Reagent preparation

Each kit contains sufficient reagents for 96 wells. This allows for the construction of one standard curve in duplicate and the assay of 36 samples in duplicate.

If you want to use the kit in two times, we provide one additional vial of Standard, one of Quality Control and one of Ellman's Reagent.

All reagents need to be brought to room temperature (around +20°C) prior to the assay.

#### **EIA Buffer**

Reconstitute the vial #A07000 with 50 mL of UltraPure water. Allow it to stand 5 minutes until completely dissolved and then mix thoroughly by gentle inversion.

Stability at 4°C: 1 month.

# Angiotensin II Standard (calibrated with the standard WHO 86/538)

Reconstitute one Angiotensin II Standard vial #A06880 with 1 mL of UltraPure water. Allow it to stand 5 minutes until completely dissolved and then mix thoroughly by gentle inversion.

The concentration of the first standard (S1) is 125 pg/mL.

Prepare seven polypropylene tubes (for the seven other standards S2 to S8) and add 500 µL of EIA buffer into each tube. Then prepare the seven standards by serial dilutions as follows:

| Standard | Volume of<br>Standard | Volume of Assay<br>Buffer | Standard concentration |
|----------|-----------------------|---------------------------|------------------------|
| S1       | -                     | -                         | 125 pg/mL              |
| S2       | 500 μL of S1          | 500 μL                    | 62.5 pg/mL             |
| S3       | 500 μL of S2          | 500 μL                    | 31.25 pg/mL            |
| S4       | 500 μL of S3          | 500 μL                    | 15.63 pg/mL            |
| S5       | 500 μL of S4          | 500 μL                    | 7.81 pg/mL             |
| S6       | 500 μL of S5          | 500 μL                    | 3.91 pg/mL             |
| S7       | 500 μL of S6          | 500 μL                    | 1.95 pg/mL             |
| S8       | 500 μL of S7          | 500 μL                    | 0.98 pg/mL             |

Stability at 4°C: 24 hours.

#### ▶ Angiotensin II Quality Control

Reconstitute one vial #A10880 with 1 mL of UltraPure Water.

Allow it to stand 5 minutes until completely dissolved and then mix thoroughly by gentle inversion.

Stability at +4°C: 24 hours.

### Angiotensin II Tracer

Reconstitute the vial #A04880 with 10 mL of EIA Buffer. Allow it to stand 5 minutes until completely dissolved and then mix thoroughly by gentle inversion.

Stability at +4°C: 1 month.

### Glutaraldehyde

Dilute 0,125 mL of concentrated Wash Buffer #A17000 with 4,875 mL of UltraPure Water. Just before use add 100 µL of glutaraldehyde #A13880 then mix thoroughly by gentle inversion.

Stability at 4°C: 24 hours.

### Borane Trimethylamine

Just before use, reconstitute one vial #A14880 with 5 mL of 2N HCI/Methanol (50/50, v/v).

Vortex until complete dissolution. At this step, bubble formation could be observed.



Once reconstituted, Borane Trimethylamine **should be used immediately** as mentioned above.

#### Wash Buffer

Dilute 2 mL of concentrated Wash Buffer #A17000 with 800 mL of UltraPure water. Add 400  $\mu$ L of Tween 20 #A12000. Use a magnetic stirring bar to mix the content. Stability at  $+4^{\circ}C$ : 1 month.

#### Ellman's Reagent

**5 minutes before use** (development of the plate), reconstitute one vial of Ellman's Reagent #A09000\_49+1 with 49 mL of UltraPure water and 1 mL of concentrated Wash Buffer #A17000. The tube content should be thoroughly mixed. Stability at +4°C and in the dark: 24 hours.

# Assay procedure

It is recommended to perform the assays in duplicate following the instructions hereafter.

#### Plate preparation

Prepare the Wash Buffer as indicated in the reagent preparation section.

Open the plate packet and select the sufficient strips for your assay and place the unused strips back in the packet. Stability at  $+4^{\circ}C$ : 1 month.


Rinse each well 5 times with Wash Buffer (300 µL/well).

Just before distributing the reagents and samples, remove the buffer from the wells by inverting the plate and shaking out the last drops on a paper towel.

### Plate set-up

A plate set-up is suggested hereafter.

The contents of each well may be recorded on the template sheet provided at the end of this technical booklet.



Bk: Blank NSB: Non Specific Binding

S1-S8: Standards 1-8 \*/QC: Samples or Quality Controls

#### Pipetting the reagents

All samples and reagents must reach room temperature prior to performing the assay.

Use different tips to pipet the buffers, standards, samples, tracer, antiserum and other reagents.

Before pipetting, equilibrate the pipette tips in each reagent. Do not touch the liquid already in the well when expelling with the pipette tip.

#### > EIA Buffer

Dispense 100 µL to Non Specific Binding (NSB) wells.

#### > Angiotensin II Standard

Dispense 100  $\mu$ L of each of the eight standards (S8 to S1) in duplicate to appropriate wells. Start with the lowest concentration standard (S8) and equilibrate the tip in the next higher standard before pipetting.

Angiotensin II Quality Control and Samples Dispense 100 µL in duplicate to appropriate wells. Highly concentrated samples may be diluted in EIA Buffer.

# Incubating the plate

Cover the plate with the cover sheet and incubate 1 hour at room temperature with gentle agitation.

### Pipetting the reagent

- > Dispense 50 µL of Glutaraldehyde to each well (except Blank (Bk) wells) and incubate for 5 minutes at room temperature with gentle agitation.
- Dispense 50 μL of Borane Trimethylamine to each well (except Blank (Bk) wells) and incubate for 5 minutes at room temperature with gentle agitation.

# Washing the plate

- > Empty the plate by turning it over.
- > Rinse each well 5 times with Wash Buffer (300 µL/well).
- At the end of the last washing step, remove the buffer from the wells by inverting the plate and shaking out the last drops on a paper towel.

### Pipetting the reagent

Dispense 100 µL of Angiotensin II Tracer to each well (except Blank (Bk) wells).

# Incubating the plate

Cover the plate with a cover sheet and incubate overnight at +4°C.

#### Developing and reading the plate

- Reconstitute Ellman's Reagent as mentioned in the Reagent preparation section.
- > Empty the plate by turning over. Rinse each well five times with 300 µL Wash Buffer. The 5<sup>th</sup> time, slightly shake the plate for 10 minutes on an orbital shaker. Then rewash five times with 300 µL Wash Buffer. At the end of the last washing step, empty the plate and blot the plate on a paper towel to discard any trace of liquid.
- Add 200µL of Ellman's Reagent to each well. Cover the plate with an aluminium sheet and incubate in the dark at room temperature. Optimal development is obtained using an orbital shaker.
- Wipe the bottom of the plate with a paper towel, and make sure that no liquid has splashed outside the wells.
- Read the plate at a wavelength between 405 and 414nm (yellow colour).
- After addition of Ellman's Reagent, the absorbance has to be checked periodically (every 30 minutes) until the maximum absorbance has reached a minimum of 0,5 A.U. blank subtracted.

# Data analysis

Make sure that your plate reader has subtracted the absorbance readings of the blank wells (absorbance of Ellman's Reagent alone) from the absorbance readings of the rest of the plate. If it is not the case, please do it.

- Calculate the average absorbance for each NSB, standard and sample.
- > For each standard, plot the absorbance on *y* axis versus the concentration on *x* axis. Draw a best-fit line through the points.
- To determine the concentration of your samples, find the absorbance value of each sample on the y axis.
- Read the corresponding value on the x axis which is the concentration of your unknown sample.
- Samples with a concentration greater than 125 pg/mL should be re-assayed after dilution in EIA Buffer.
- Most plate readers are supplied with a curve-fitting software capable of graphing these data (4-parameter logistic fit 4PL). If you have this type of software, we recommend using it. Refer to it for further information.



Two vials of Quality Control are provided with this kit.

Your standard curve is validated only if the calculated concentration of the Quality Control obtained with the assay is +/- 25% of the expected concentration (see the label of QC vial).

# Acceptable range

- > Non-specific Binding <150 mAU
- > Limit of detection <5 pg/mL
- Quality Control ±25% of the expected concentration (see the label on QC vial)


# Typical results

The following data are for demonstration purpose only. Your data may be different and still correct.

These data were obtained using all reagents as supplied in this kit under the following conditions: 1 hour developing at +20°C, reading at 414 nm. A linear-curve fitting was used to determine the concentrations.

|             | Angiotensin II<br>(pg/mL) | Absorbance<br>(mAU) |
|-------------|---------------------------|---------------------|
| Standard S1 | 125                       | 2,069               |
| Standard S2 | 62.5                      | 1,156               |
| Standard S3 | 31.25                     | 636                 |
| Standard S4 | 15.63                     | 359                 |
| Standard S5 | 7.81                      | 211                 |
| Standard S6 | 3.9                       | 140                 |
| Standard S7 | 1.95                      | 101                 |
| Standard S8 | 0.98                      | 82                  |
| NSB         | -                         | 57                  |

Typical Angiotensin II standard curve



# Assay validation and characteristics

The Enzyme Immunometric Assay of Angiotensin II has been validated for its use in plasma after extraction.

For additional information regarding the validation of immunoassay for protein biomarkers in biological samples, please refer to bibliography [9, 10].

- > The Minimum Detectable Concentration (MDC) or Sensitivity of Angiotensin II corresponding to the NSB average plus three standard deviations (n = 8) is: 1 pg/ mL.
- > Limit of quantification: 2 pg/mL
- > Quality Control (QC) samples intra & inter-assay variation: established by measuring each QC five times per assay and in six different assays (i.e. 30 assays per QC)

| pg/mL | Intra-assay coefficient of variation | Inter-assay coefficient of variation |  |
|-------|--------------------------------------|--------------------------------------|--|
| 100   | 7 %                                  | 7 %                                  |  |
| 20    | 2 %                                  | 5 %                                  |  |
| 5     | 6 %                                  | 10 %                                 |  |
| 2     | 10 %                                 | 14.5 %                               |  |


#### Cross-reactivity [5]


The peptidic sequence for Angiotensin II is highly conserved across mammalian species, this is why our kit cross-reacts with all mammalian samples.


| Angiotensin II  | 100 %   |
|-----------------|---------|
| Angiotensin I   | 4 %     |
| Angiotensin III | 36 %    |
| Angiotensin 3-8 | 33 %    |
| Angiotensin 1-7 | <0.01 % |

#### > Specificity


Comparison of HPLC profiles of Angiotensin standards, a blank sample and a plasma sample.







#### Comparison with RIA on 29 samples



# Troubleshooting

- Absorbance values are too low:
  - incubation in wrong conditions (time or temperature),
  - reading time too short,
  - Tracer, Glutaraldehyde, Wash Buffer or Borane Trimethylamine have not been dispensed,
  - organic contamination of water.

#### NSB value too high:

- contamination of NSB wells with Angiotensin II standard,
- inefficient washing,
- Borane Trimethylamine has been dispensed not on time or not at all.

#### > High dispersion of duplicates:

- poor pipetting technique
- irregular plate washing.
- If a plate is accidentally dropped after dispatch of the AChE® substrate (Ellman's Reagent) or if it needs to be revealed again:
  - one only needs to wash the plate, add fresh Ellman's Reagent and proceed with a new development.
  - Otherwise, the plate can be stored at +4°C with wash buffer in wells while waiting for technical advice from the Bioreagent Department.

These are a few examples of troubleshooting that may occur.

If you need further explanation, Bertin Pharma will be happy to assist you. Feel free to contact our technical support staff by

phone (+33 (0)139 306 036), fax (+33 (0)139 306 299) or E-mail (bioreagent@bertinpharma.com), and be sure to indicate the batch number of the kit (see outside the box).

Bertin Pharma proposes EIA Training kit #B05005 and EIA workshop upon request. For further information, please contact our Marketing Department by phone (+33 (0)139 306 260) or E-mail (marketing@bertinpharma.com).

# Bibliography

1. Grassi J., Pradelles P.

Compounds labelled by the acetylcholinesterase of *Electropho-rus Electricus*. Its preparation process and its use as a tracer or marquer in enzymo-immunological determinations. *United States patent*, *N°* 1,047,330. September 10, 1991

Grassi J., Pradelles P.

The use of Acetylcholinesterase as a Universal marker in Enzyme-Immunoassays.

Proceedings of the Third International Meeting on Cholinesterases, American Chemical Society (1991)

3. Pradelles P., Grassi J., Maclouf J.

Enzyme Immunoassays of Eicosanoids Using Acetylcholinesterase.

Methods in Enzymology (1990), vol. 187, 24-34

4. Paulis L, Unger T.

Novel therapeutic targets for hypertension.

Nat Rev Cardiol. 2010 Aug; 7(8): 431-41

5. Volland H., Pradelles P., Ronco P. et al.

A solid-phase immobilized epitope immunoassay (SPIE-A) permitting very sensitive and specific measurement of angiotensin II in plasma.

J Immunol Methods. 1999 Aug 31; 228(1-2): 37-47

Pradelles P.

Immunometric determination of an antigen or hapten. *United states patent, N°5,476,770. December 19; 1995* 

- Kohara K., Tabuchi Y., Senanayake P., Brosnihan KB, Ferrario CM. Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures. Peptides. 1991 Sep-Oct; 12(5):1135-41
- 8. Grassi J., Créminon C., Frobert Y., Etienne E, Ezan E, Volland H, Pradelles P.

Two different approaches for developing immunometric assays of haptens.

Clin Chem. 1996 Sep; 42(9): 1532-6

Valentin MA, Ma S, Zhao A, Legay F, Avrameas A
 Validation of immunoassay for protein biomarkers: Bioanalytical study plan implementation to support pre-clinical and clinical studies.

J Pharm Biomed Anal. (2011) 55(5): 869-877

10. European Medicines Agency

Guideline on bioanalytical method validation, 21 July 2011

#### Additional readings

List of publications quoting the use of this kit.

- Efrati S., Berman S., Hamad RA., et al.
   Effect of captopril treatment on recuperation from ischemia/ reperfusion-induced acute renal injury.
   Nephrol Dial Transplant. 2012 Jan; 27(1):136-45
- Dagan A., Gattineni J., Habib S., et al.
   Effect of Prenatal Dexamethasone on Postnatal Serum and Urinary Angiotensin II Levels.
   Am J Hypertens 2010; 23:420-424

13. Feng Y-H., Zhou L., Qiu R., et al.

Single Mutations at Asn295 and Leu305 in the Cytoplasmic Half of Transmembrane a-Helix Domain 7 of the AT1 Receptor Induce Promiscuous Agonist Specificity for Angiotensin II Fragments: A Pseudo-Constitutive Activity.

Molecular Pharmacology August 2005, 68 (2) 347-355

14. VA S., Saad S., Poronnik P., et al. The role of SGK-1 in angiotensin II-mediated sodium reabsorption in human proximal tubular cells. Nephrol Dial Transplant. 2008 Jun; 23(6):1834-43

15. Yanes LL., Romero DG., Iles JW., et al. Sexual dimorphism in the renin-angiotensin system in aging spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2006 Aug; 291(2):R383-90

16. Yvan-Charvet L., Massiéra F., Lamandé N., et al. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue.

Endocrinology. 2009 Mar; 150(3): 1421-8

17. Van Ginkel A., De Haan b., et al. Exercise intensity modulates capillary perfusion in correspondence with ACE I/D modulated serum angiotensin II levels

Applied & Translational Genomics 4 (2015) 33-37

18. Kawaguchi, Takagi et al.

Angiotensin II in the Lesional Skin of Systemic Sclerosis

Patients Contributes to Tissue Fibrosis Via Angiotensin II Type 1

Receptors


Arthritis & Rheumatism, Vol. 50, No. 1, January 2004, 216–226

19. Miceli, Burt et al.

Stretch reduces nephrin expression via an angiotensin II-AT1-dependent mechanism in human podocytes: effect of rosiglitazone

Am J Physiol Renal Physiol 298: F381–F390, 2010

This document is copyrighted. All rights are reserved. This document may not, in whole or part, be copied, photocopied, reproduced, translated, or reduced to any electronic medium or machine readable form without the prior consent, in writing, from Bertin Pharma.





Bertin Pharma, over the last decades, has been developing and marketing over 100 biomarker assays, pre-analytical products, kits, antibodies and biochemicals thanks to its innovative work in research and development. Our core areas are orientated to inflammation, oxidative injury, endocrinology, diabetes, obesity, hypertension, neurodegenerative diseases, HIV, prion diseases, pharmacokinetics and metabolism.

Bertin Pharma is active worldwide either with direct sales or through our qualified and trained international distribution network from the United States to Japan.

We are able to provide you with local technical support to use at ease our products.

For further information, please send your request to bioreagent@bertinpharma.com

